Izvorni znanstveni članak
Comparison Between Clinical Significance of Serum Proinflammatory Protein Interleukin-6 and Classic Tumor Markers Total PSA, Free PSA and Free/Total PSA Prior to Prostate Biopsy
Nevenka Miličević
; 1 »J. J. Strossmayer« University, University Hospital Centre Osijek, Reanimatology and Intensive Care Unit, Department of Anesthesiology, Osijek, Croatia
Milanka Mrčela
; »J. J. Strossmayer« University, University Hospital Centre Osijek, Department of Pathology and Forensic Medicine, Osijek, Croatia
Ivana Lukić
; »J. J. Strossmayer« University, School of Medicine, Osijek, Croatia
Sanja Mandić
; »J. J. Strossmayer« University, University Hospital Centre Osijek, Department of Clinical Laboratory Diagnostics, Osijek, Croatia
Vesna Horvat
; »J. J. Strossmayer« University, University Hospital Centre Osijek, Department of Clinical Laboratory Diagnostics, Osijek, Croatia
Josip Galić
; »J. J. Strossmayer« University, University Hospital Centre Osijek, Clinic of Urology, Osijek, Croatia
Sažetak
The aim of the study was to clarify whether serum levels of proinflammatory cytokine interleukin-6 (IL-6) could be a useful marker in prostate diseases. Serum IL-6 was determined prior to prostate biopsy procedure in 82 patients with prostate adenocarcinoma (PCa), 25 patients with benign prostatic hyperplasia (BPH), 24 patients with high-grade prostatic intraepithelial neoplasia (PIN) and 17 patients with chronic prostatitis. Serum IL-6 levels were compared with total PSA (tPSA), free PSA (fPSA) and the free/total ratio (f/tPSA) serum levels. Statistically significant difference was not found in serum IL-6 levels among the four groups (p=0.088). However, the patients with poorly differentiated PCa with Gleason score (GS) 4+3=7 and >7 had significantly higher serum IL-6 levels than the patients with moderately differentiated PCa with GS 3+4=7 and <7 (p=0.007). The findings suggest that serum IL-6 level might be a potentially useful marker for poorly differentiated PCa.
Ključne riječi
interleukin-6; serum levels; prostate biopsy; prostate-specific antigen; Gleason score
Hrčak ID:
120866
URI
Datum izdavanja:
31.3.2014.
Posjeta: 1.505 *